eXoZymes · ISIN: US4618741098

eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST

LOS ANGELES, CA / ACCESS Newswire / August 7, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Tuesday, August 12, 2025 at 5:00 PM Eastern Time to discuss its result...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 07.08.2025 | 18:35
07 August 2025 06:35PM
eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST
LOS ANGELES, CA / ACCESS Newswire / August 7, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Tuesday, August 12, 2025 at 5:00 PM Eastern Time to discuss its result...
eXoZymes
© ACCESSWIRE
29 July 2025 07:57AM
eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity
Using eXoZymes' AI-driven exozymes platform, NCTx has demonstrated lab scale validation with 4 grams of NCT produced at a 96% yield and with a purity higher than 99%.NCT project went from concept to gram scale production in 5 months and at a fraction of normal SynBio R&D cost.N-trans-caffeoyltyramine (NCT) is a natural product compound attracti...
eXoZymes
© ACCESSWIRE
22 July 2025 04:10PM
eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months
N-trans-caffeoyltyramine (NCT) is a natural bioactive compound attracting considerable interest from researchers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.Using eXoZymes' AI-driven platform, a new and proprietary approach to biomanufacturing of NCT - with all the scale-up advantages of...
eXoZymes
© ACCESSWIRE
26 June 2025 04:10PM
eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing
MONROVIA, CA / ACCESS Newswire / June 26, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its role in the Meta-PURE initiative, a $9.2 million USD National Science Foundation (NSF)...
eXoZymes
© ACCESSWIRE
16 May 2025 09:25AM
eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast
MONROVIA, CALIFORNIA / ACCESS Newswire / May 16, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - was featured on the latest episode of the Grow Everything podcast, revealing how the company's...
eXoZymes
© ACCESSWIRE
12 May 2025 04:10PM
eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today
Management to host earnings call at 5:00PM Eastern Time, today. MONROVIA, CA / ACCESS Newswire / May 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential nutraceuticals, medicines, biofuels, and other valuable chemicals - provides an update...
eXoZymes
© ACCESSWIRE
07 May 2025 05:20PM
eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST
MONROVIA, CA / ACCESS Newswire / May 7, 2025 / eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Monday, May 12, 2025 at 5:00 PM Eastern Time to discuss its results for the first q...
eXoZymes
© ACCESSWIRE
06 May 2025 04:10PM
eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health
N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.eXoZymes used its AI-driven development platform to progress from idea to purpose-built subsidiary in less than 3...
eXoZymes
© ACCESSWIRE
21 April 2025 08:10PM
Bringing clarity and precision to the cell-free space by introducing exozymes
...
eXoZymes
© Globe Newswire
02 April 2025 08:10PM
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
...
eXoZymes
© Globe Newswire
26 March 2025 09:00PM
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025
Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on Wednesday, April 2, 2025 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter an...
eXoZymes
© Globe Newswire
21 February 2025 09:05PM
eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc.
Monrovia, CA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ, formerly Invizyne Technologies) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - and MDB Capital Holdings (NASDAQ: MDBH) - a premier venture platform for breakthrough technology companies -...
eXoZymes
© Globe Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.